ANI Pharmaceuticals Inc ANIP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $83.00
- Day Range
- $82.12–83.13
- 52-Week Range
- $62.79–99.48
- Bid/Ask
- $82.37 / $83.02
- Shares Outstanding
- 22.73M
- Market Cap
- $1.89B
- Volume/Avg
- 13,022 / 346,478
Key Statistics
- Price/Earnings (Normalized)
- 9.94
- Price/Sales
- 1.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.66%
Company Profile
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 970
Valuation
|
Metric
|
ANIP
|
|---|---|
Price/Earnings (Normalized) | 9.94 |
Price/Book Value | 3.32 |
Price/Sales | 1.91 |
Price/Cash Flow | 8.14 |
Price/Earnings
ANIP
Financial Strength
|
Metric
|
ANIP
|
|---|---|
Quick Ratio | 2.43 |
Current Ratio | 3.12 |
Interest Coverage | 7.32 |
Quick Ratio
ANIP
Profitability
|
Metric
|
ANIP
|
|---|---|
Return on Assets (Normalized) | 12.43% |
Return on Equity (Normalized) | 34.83% |
Return on Invested Capital (Normalized) | 16.60% |
Return on Assets
ANIP
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Vwpnlgtkc | Xfzzf | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Hsyhffvcx | Pmsbtzt | $40B | |||
| Haleon PLC ADR
HLN
| Zwflnqpw | Tjf | $40B | |||
| Zoetis Inc Class A
ZTS
| Zmvrckpn | Zyzf | $33B | |||
| Viatris Inc
VTRS
| Zgsbpyptc | Rqwpt | $19B | |||
| Elanco Animal Health Inc
ELAN
| Yblb | Tvtq | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Bflttndsn | Clph | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Lryntmcm | Kxc | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Tmxmwfcj | Fyqssj | $2B | |||
| Perrigo Co PLC
PRGO
| Sznzqptxf | Tbd | $2B |
United States